Replimune Group is a clinical-stage biotechnology company that focuses on developing novel oncolytic immunotherapies. Their proprietary RPx platform uses a modified strain of herpes simplex virus 1 to activate the immune system against solid tumors. The company aims to improve the effectiveness of virus replication and the immune response to tumor antigens. Replimune plans to rapidly advance these therapies through clinical trials and combine them with other immuno-oncology products. Their goal is to develop powerful therapies that can overcome cancer and treat a wide range of tumor types.